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Abstract We have cloned a cDNA encoding a novel association 
partner of cyclin G by West-Western blotting. The cDNA 
encodes a protein that harbors a Ser/Thr protein kinase-like 
catalytic domain at the N-terminal. Hence, we named it GAK 
(cyclin G-associated kinase). The long C-terminal extension 
shares homology with tensin and auxilin, and contains a leucine 
zipper region. Co-immunoprecipitation and Western blotting 
showed that GAK and cyclin G associate together in vivo. GAK 
also co-precipitated with CDK5, and CDK5 was found to be 
associated with cyclin G. We also showed by BIAcore analysis 
that the GAK-cyclin G interaction was direct. 
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1. Introduction 
The cell cycle of eukaryotes is regulated by cyclins and 
cyclin-dependent protein kinases (CDKs) [1-3]. Several spe-
cies of cyclin-CDK complexes have been identified and shown 
to regulate different transitions in the cell cycle. Previously, we 
found a new cyclin (cyclin G) [4] that is homologous to hu-
man cyclin A and fission yeast Cigl [5,6]. The recent discovery 
that cyclin G is a direct transcriptional target of the product 
of the p53 tumor suppressor gene highlighted its potential 
importance as a possible mediator between apoptosis and 
the cell cycle [7,8]. Transcription of cyclin G is induced within 
a few hours of growth factor stimulation of quiescent cells [4]. 
A retroviral vector-mediated gene transfer of antisense cyclin 
G inhibited proliferation of human osteogenic sarcoma cells 
[9], suggesting a pivotal role for cyclin G in growth regulation 
of mammalian cells. Otherwise, neither the biochemical regu-
latory mechanism nor the physiological function of cyclin G 
has been defined. In order to investigate the physiological role 
of cyclin G, we have searched for the proteins that associate 
with cyclin G by screening West-Western blots. Here we re-
port the cloning of a c D N A encoding a novel Ser/Thr kinase 
which we call G A K , and demonstrate that it directly associ-
ates with cyclin G using two different techniques. 
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2. Materials and methods 
2.1. Antibodies 
Anti-GAK monoclonal antibodies (1E1 and 1C2) were produced by 
immunization with the rat GST-GAK fusion protein according to 
standard methods [10]. Anti-cyclin G (pGpep and pCyG) and anti-
GAK (pGAK) polyclonal antibodies were raised by standard tech-
niques in New Zealand White rabbits with the synthetic peptide of 
rat cyclin G (CTLPFERRNDLNFERL) and rat GST-GAK as anti-
gens, respectively. Anti-CDC2 (MBL, Nagoya), anti-CDK2 (MBL), 
and anti-CDK5 (Santa Cruz Biotechnology, Santa Cruz, CA) mono-
clonal antibodies, and anti-cyclin Dl (MBL), anti-cyclin Bl (Onco-
gene Science), anti-cyclin E (UBI, New York), anti-CDK6, anti-
CDK7 (Santa Cruz Biotechnology), and anti-CDK4 (UBI) polyclonal 
antibodies were purchased from the specified companies. 
2.2. Molecular cloning of GAK 
A rat fibroblast (3Y1) cDNA library was prepared using the XZapII 
vector (Stratagene, San Diego, CA), lysed and transferred to nitro-
cellulose filters. The filters were incubated with the GST-cyclin 
G fusion protein for several hours at 4°C in TBST buffer. The fil-
ters were screened using our anti-cyclin G polyclonal antibody, which 
was raised against the synthetic peptide of rat cyclin G 
(CTLPFERRNDLNFERL). Subsequently, the filters were incubated 
with anti-rabbit Ig antibody conjugated to alkaline phosphatase, 
which enabled the positive clones to be visualized by reaction with 
NBT (nitroblue tetrazolium) and BCIP (5-bromo-4-chloro-3-indoyl 
phosphate). Xphage clones yielding duplicate positive signals were 
turned into plasmid forms by the SOLR system (Stratagene) and 
were subjected to further analysis. The DNA sequence of both strands 
was determined by the chain termination reaction. 
2.3. Binding ability of anti-cyclin G and anti-GAK antibodies to GST 
fusion proteins 
GST fusion proteins (1 ug) and relevant antibodies (1 ug) were 
mixed in PBS supplemented with protease inhibitors (100 mM 
PMSF, 1 ug/ml leupeptin, 1 ug/ml aprotinin and 1 ug/ml pepstatin 
A). The mixture was rotated at 4°C for 2 h, and 40 ul of 50% gluta-
thione-Sepharose 4B was added. After further rotation at 4°C for 2 h, 
the complex of GST fusion protein and antibody was precipitated 
with glutathione beads. The beads were washed 3 times with 500 ul 
of PBS supplemented with protease inhibitors and mixed with 20 ul of 
SDS-PAGE sample buffer. After boiling for 5 min, 5 ul of each sam-
ple was loaded on a 10% SDS-PAGE gel and subjected to Western 
blotting as described below. Precipitated and blotted antibodies were 
detected with horseradish peroxidase-conjugated anti-mouse IgG plus 
anti-rabbit IgG. 
2.4. Immunoprecipitation and Western blotting 
Immunoprecipitation was done by collecting and lysing subconflu-
ent NRK cells in lysis buffer (50 mM Tris-HCl, pH 7.5, 250 mM 
NaCl, 0.1% NP40) supplemented with protease inhibitors and phos-
phatase inhibitors (10 mM Na4P207 , 10 mM NaF, 2 mM sodium 
vanadate and 1 mM EGTA). After clarifying the extract by centrifu-
gation at lOOOOXg for 5 min, aliquots of the supernatant were im-
munoprecipitated by protein A-Sepharose alone. The precleared ly-
sates were subsequently immunoprecipitated by the relevant 
antibodies. For Western blot analysis, equal quantities of fresh or 
immunoprecipitated cell extract were adsorbed to protein A-Sephar-
ose, separated by 10% SDS-PAGE, transferred onto Immobilon mem-
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brane (Millipore) and probed with indicated antibodies in TBST buf-
fer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween-20). 
Immunoreactive protein bands were visualized by ECL (Amersham, 
UK) or RENAISSENSE (Dupont, Boston, MA) chemiluminescence 
reagents. The prestained size marker was purchased from BioRad. 
2.5. Preparation of Myc-tagged cyclin G and transformation of COS7 
cells 
The wye-tagged cyclin G cDNA was synthesized by PCR (with Pfu 
DNA polymerase) using the 5' primer 5'-ACGCGTAAGATGGAA-
CAAAAGCTTATTTCTGAAGAAGACTTGATAGAAGTACTGA-
CAACTGAC-3' (where the underlined sequence is the sense sequence 
coding for a C-terminal 9E10 myc epitope) and the 3' primer 5'-
CGTCGAATTCTAACCCATGGTTTCGGG-3' with rat cyclin G 
cDNA as a template. The PCR product generated was digested 
with Pstl/EcoRI, and inserted into the PstllEcoRl site of the pAP3neo 
vector (Nojima, unpublished). The plasmid DNA was transfected into 
COS7 cells using lipofectamine (Gibco-BRL, Gaithersburg, MD). 
Anti-myc monoclonal antibody was purchased from Oncogene Sci-
ence. 
2.6. Association of GAK with cyclin G in vitro as assessed by BIAcore 
In order to perform analysis with a surface plasmon resonance 
biosensor (BIAcore, Pharmacia), polyclonal antibody against GST 
(Pharmacia) was immobilized onto a dextran flow cell matrix (Sensor 
chip CM5, Pharmacia) at an amount corresponding to 1000 R ( ~ 1.0 
ng/mm2). 50 ul of GST-GAK (1 uM) was injected and trapped by the 
antibody via the GST portion of the molecule. Subsequently, 40 JJ.1 of 
affinity purified cyclin G (0.5-2.0 uM) or Hacl (1 (iM) was injected to 
detect any interactions. All sensograms were recorded at a flow rate of 
5 ul/min at 20°C in HBS (10 mM HEPES, pH 7.4, 150 mM NaCl, 
1 mM MgCl2, 1 mM CaCl2, 10 mM sodium azide, 0.05% Tween-20). 
At the end of each measurement, immobilized GST antibody was 
regenerated using 0.1 M glycine-HCl (pH 2.5), and the same amount 
of a new GST-GAK sample was injected to monitor separate inter-
actions. Kinetic data were analyzed using standard kinetic equations 
[11] implemented in a software package (Kinetics Evaluation) supplied 
by Pharmacia Biosensor and run on a Compaq PC. 
3. Results 
3.1. Molecular cloning of GAK 
To search for the cDNA encoding an association partner of 
cyclin G, we prepared a rat fibroblast (3Y1) cDNA library 
with the AZapII vector and screened it by West-Western blot-
ting using an anti-cyclin G polyclonal antibody. Of about a 
million phages, seven A.phage clones showed positive signals. 
The DNA sequence, as determined by the chain termination 
reaction, revealed that one of the clones encoded a novel Ser/ 
Thr protein kinase (1305 amino acids), which we named 
GAK, an acronym for cyclin G-associated kinase. The details 
of the other clones will be published elsewhere. 
The amino acid sequence of the cDNA, as deduced from 
the DNA sequence, indicated that the structure of the kinase 
domain closely resembles that of Nek 1 [12], CDK2 [2,13,14], 
Plk [14] and Tsk-1 [15] kinases (Fig. 1A,B). As GAK lacks a 
PSTAIR motif, the amino acid sequence found in all CDKs, it 
cannot be considered a member of the CDK family. In the 
middle part of the molecule (Fig. 1C), GAK resembles both 
tensin, an actin-binding component of adhesion plaques (also 
called focal contacts) and other submembranous cytoskeletal 
structures [16], and auxilin, a coat component of brain cla-
thrin-coated vesicles [17,18]. The domain homologous to ten-
sin and auxilin (we call it the TAG domain hereafter) occupies 
more than half of the whole molecule and contains, in addi-
tion, a leucine zipper region [19] in the C-terminal portion of 
this domain. In the C-terminal domain of the molecule (132 
amino acids), GAK and auxilin are up to 80% identical, and 
this region is very rich in serine and proline residues (14% and 
18% respectively). A phosphorylation recognition site for a 
tyrosine kinase is located at position 403-410 (KGDLDISY) 
[20-22] at the left end of the TAG domain. This recognition 
site is also found in auxilin (KGDLDFTY at position 58-65) 
but the sequence is less conserved in tensin (SCELDLVY at 
position 64-71). The kinase domain of GAK harbors two 
putative nucleotide binding sequences (GXGXXG) at posi-
tions 13-18 and 337-342 [23]. One (KKLS at position 90-
93), 19 and 24 potential phosphorylation sites for cAMP-de-
pendent protein kinase, protein kinase C and casein kinase II 
protein kinase, respectively, were also found (locations are not 
shown). A hydropathy plot [24] suggests that the overall struc-
ture of GAK is hydrophilic and no conspicuous cluster of 
hydrophobic regions could be found (data not shown). 
A Northern blot showed that GAK mRNA occurs as a 
single band in NRK cells (data not shown), whose size (about 
4.4 kb) is similar to that of the cDNA we cloned. Although 
auxilin is transcribed specifically in neural cells, GAK mRNA 
was ubiquitous and was expressed at variable levels in all the 
tissues we examined (data not shown). 
3.2. Characterization of the antibodies 
We prepared six kinds of antibodies, namely two anti-cyclin 
G (pGpep and pCyG) polyclonal antibodies, one anti-GAK 
polyclonal antibody (pGAK) and three anti-GAK monoclo-
nal antibodies (1E1, 1C2 and 3H9). pGpep antibody, which 
we used for West-Western screening, binds to native GST-
cyclin G and was useful for West-Western screening, GST 
pull-down experiment (Fig. 2A, lane 3) and immunoprecipita-
tion (Fig. 3C, lane 12). The positive signal obtained by West-
Western screening was not due to cross-reactivity of the anti-
body to GAK, because the GST-GAK fusion protein was not 
recognized by this antibody (lane 2). It was found that pGpep 
antibody did not effectively detect the cyclin G band on West-
ern blots. Therefore, we purchased anti-cyclin G antibody 
from Santa Cruz Biotechnology to perform Western analysis. 
This antibody was also effective for immunoprecipitation as 
judged by the GST pull-down experiment (lanes 5 and 6) 
compared to the negative control (lanes 2 and 7). We did 
not use pCyG (lane 4) since it showed similar properties to 
pGpep. 
All of the anti-GAK antibodies seem to recognize the de-
natured form of GST-GAK, which was largely degraded dur-
ing the purification process (Fig. 2B, lanes 2, 4, 6 and 8). Anti-
GAK polyclonal antibody (pGAK) was useful for immuno-
Fig. 1. Structure of GAK. A: Schematic presentation of the structure of rat GAK, tensin [16] and auxilin [17]. The consensus domain for Ser/ 
Thr kinases (filled box), the conserved domains between GAK and auxilin (shaded box), and homologous regions between GAK, tensin and 
auxilin (TAG domain as stippled box) are indicated. The locations of the nucleotide binding sequences (GXGXXG), the phosphorylation site 
for tyrosine kinase (KGDLDISY), and the leucine zipper are also shown. B: Amino acid sequence of rat GAK. The Ser/Thr kinase domain, 
TAG domain and the region homologous to auxilin are encircled. The locations of the phosphorylation site for tyrosine kinase (filled bar), and 
for the leucine zipper (filled circles) are denoted. C: Comparison of the amino acid sequences of GAK, auxilin and tensin. Shaded boxes repre-
sent identical amino acids. 
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Fig. 2. Characterization of cellular GAK protein and anti-cyclin G or anti-GAK antibodies. A: Binding ability of anti-cyclin G antibodies to 
GST-cyclin G. GST-cyclin G was mixed with the anti-cyclin G peptide (pGpep; lane 3) used for West-Western screening, anti-GST-cyclin G 
(pCyG; lane 4), anti-rat cyclin G of Santa Cruz (cyclin G; lane 5), anti-human cyclin G of Santa Cruz (hCyclin G; lane 6), or preimmune se-
rum (PS; lane 7). Subsequently, these samples were precipitated with glutathione-Sepharose 4B, precipitated, Western-blotted and probed with 
anti-IgG antibody. To show the absence of cross-reaction of the antibodies with the GST portion of GST-cyclin G, pGpep was mixed with 
GST-GAK (lane 2). As a positive control for the IgG band, 1 ug of normal rabbit IgG was loaded on the same gel (lane 1). Because all of the 
polyclonal antibodies were prepared by immunizing rabbits, the affinity of the HRP-conjugated secondary anti-rabbit IgG antibody to the sam-
ples in lanes 3-7 are expected to be equal. B: Quality of anti-GAK antibodies used in the experiments. Lysates (20 jig) of NRK cells growing 
in log phase (lanes 1, 3, 5 and 7), or affinity-purified GST-GAK (100 |xg; filled triangles denote full-length GST-GAK in lanes 2, 4, 6 and 8) 
were loaded, Western-blotted and probed with monoclonal (1C2, 3H9 or 1E1) or polyclonal (pGAK) anti-GAK antibodies. C: Binding ability 
of anti-GAK antibodies to GST-GAK was assessed as described in A by mixing GST-GAK with preimmune serum (lane 1), anti-GAK poly-
clonal antibody (lane 2), anti-GAK monoclonal antibodies (lanes 3, 4 and 5). Normal rabbit IgG was loaded on the gel (lane 6). D: Immuno-
precipitation of GAK in NRK cell lysates with anti-GAK antibodies. NRK cell extract (500 |xg) was immunoprecipitated with preimmune se-
rum (lane 1), 1E1 (lane 3), 1C2 (lane 4) and pGAK (lane 5). NRK cell extract (20 ug) was also electrophoresed (lane 2) to assign the GAK 
band. 
precipitation (Fig. 2C, lane 2; Fig. 2D, lane 5) but detected 
bands other than the intact GAK band when used for West-
ern analysis (Fig. 2B, lane 7). An anti-GAK monoclonal anti-
body (1E1) was useful for immunostaining (data not shown) 
and Western blotting, although it also detected extra bands 
(Fig. 2B, lane 5). On the other hand, two anti-GAK mono-
clonal antibodies (1C2 and 3H9) displayed essentially a single 
band for GAK with high sensitivity in Western blotting (Fig. 
2B, lanes 1 and 3). However, these monoclonal antibodies did 
not recognize the native form of GST-GAK (Fig. 2C, lane 3, 
4 and 5), and for that reason the native form of GAK was 
only inefficiently immunoprecipitated from the NRK extract 
(Fig. 2D, lanes 3 and 4). Therefore, we primarily used pGAK 
for immunoprecipitation, pGAK or 1E1 for immunostaining 
(data not shown), and 1E1, 1C2 or 3H9 for Western blot 
analysis. 
3.3. Association of GAK with cyclin G in vivo 
We demonstrated an association of GAK with cyclin G in 
vivo by performing immunoprecipitation of NRK (normal rat 
fibroblast) cell extracts with an antibody directed against rat 
cyclin G (Santa Cruz), followed by Western blotting the im-
munoprecipitates with an anti-GAK monoclonal antibody 
(1C2) (Fig. 3A-i, lane 3). We also demonstrated their associ-
ation by reciprocal immunoprecipitation (with pGAK) and 
Western blotting (Fig. 3A-ii, lane 1). In both cases, the im-
munoprecipitates with preimmune serum (PS) yielded no band 
and were used as negative controls (Fig. 3A-i, lane 2 and Fig. 
3A-ii, lane 4). Pre-treatment of anti-GAK antibody with af-
finity-purified GST-fused GAK protein weakened the inten-
sity of the band at 33kD (Fig. 3A-ii, lanes 2 and 3). This result 
suggests that the binding of anti-cyclin G antibody to GAK 
was competitive. It remains to be investigated whether the 
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Fig. 3. Association of GAK with cyclin G and CDK5 in vivo. A: Association of GAK with cyclin G in vivo, (i) 10 (ig of NRK cell extract 
was electrophoresed (lane 1) to assign the GAK band. 500 ug of NRK cell extract was immunoprecipitated with preimmune serum (lane 2) or 
with anti-cyclin G polyclonal antibody (Santa Cruz; lane 3) and immunoblotted with anti-GAK monoclonal antibody (1C2). The band for 
GAK observed in lanes 1 and 3 but not in lane 2 is denoted by an arrow, (ii) NRK cell extract (500 ug) was immunoprecipitated with anti-
GAK polyclonal antibody (lanes 1-3), or preimmune serum (lane 4) and immunoblotted with anti-cyclin G polyclonal antibody. 10 ug (lane 2) 
or 3.5 ug (lane 3) of affinity-purified GST-GAK protein was preadsorbed to the anti-GAK polyclonal antibody (pGAK) to conduct competi-
tion experiments, (iii) COS7 cell extracts transfected by the plasmid DNA with (lanes 1 and 3) or without (lanes 2 and 4) myc-tagged cyclin G 
were immunoprecipitated and immunoblotted with either anti-myc (lanes 1 and 2) or anti-GAK (lanes 3 and 4) antibodies. Arrows denote the 
band for m_yc-tagged cyclin G, indicating successful expression, and for GAK, demonstrating a stable in vivo association with myc-tagged cyclin 
G. B: Association of CDK5 with either GAK (lane 6) or cyclin G (lane 8), demonstrated by immunoprecipitation with corresponding antibod-
ies and Western analysis with anti-CDK5 (DC17) monoclonal antibody. C: Association of GAK with either CDK5 (lane 6) or cyclin G (lane 
12), demonstrated by immunoprecipitation with corresponding antibodies and Western analysis with anti-GAK monoclonal antibody (1C2). 
Western analysis was performed on NRK extracts (denoted as NRK log) and on immunoprecipitates obtained with anti-cyclin E, anti-cyclin 
Bl, anti-cyclin Dl , anti-cyclin G (pGpep), anti-CDK4, anti-CDK6, anti-CDK7 or anti-GAK polyclonal antibodies or with anti-CDC2 (2A10), 
anti-CDK2 (8A12) or anti-CDK5 (DC17) monoclonal antibodies. Rabbit preimmune serum (PS) was also used for immunoprecipitation as a 
negative control. 
unidentified upper bands observed in lanes 2-4 of Fig. 3A-ii 
are modified forms of cyclin G or contaminant proteins. As-
sociation of GAK with cyclin G in vivo was further confirmed 
by immunoprecipitation of a COS7 cell extract bearing exog-
enously expressed »yc-tagged cyclin G with anti-myc mono-
clonal antibody, followed by Western blotting with an anti-
GAK monoclonal antibody (1E1) (Fig. 3A-iii, lane 3). Suc-
cessful expression of myc-tagged cyclin G was demonstrated 
by Western analysis of the blot with an anti-myc antibody 
(Fig. 3A-iii, lane 1). The myc-tagged cyclin G migrated to a 
slightly different location compared to the native cyclin G 
because of the presence of additional myc peptides at the N-
terminus. 
To examine whether GAK is the only cyclin G-associated 
kinase, association of cyclin G with other known CDKs was 
examined by immunoprecipitation and Western blotting. No 
association was detected when an NRK extract was immuno-
precipitated by anti-cyclin G antibody and Western blotted 
with antibodies directed against CDC2, CDK2, CDK4 and 
CDK6 (data not shown). On the other hand, association of 
cyclin G with CDK5 was demonstrated when anti-cyclin G 
immunoprecipitates were subjected to Western analysis and 
probed with anti-CDK5 antibody as shown in Fig. 3B (lane 
8), although the intensity of the band was very faint. It re-
mains to be established whether the weak intensity of the 
band is due to inefficient immunoprecipitation with anti-cyclin 
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Fig. 4. Association of the affinity-purified GST-GAK fusion protein with cyclin G in vitro. A: Overlay presentation of the sensograms for the 
association of GST-GAK/cyclin G and GST-GAK/Hacl. B: The slope of the interaction curve at each cyclin G concentration was used for ki-
netic analysis. Purified cyclin G protein was added at various concentrations ranging from 0.5 |iM to 2 uM in HBS buffer. The association 
constant fcass was obtained from the slope of the fitted line. C: Dissociation of GAK-GST and cyclin G under continuous buffer flow. The dis-
sociation rate (fcdiss) was obtained from the slope of the ln(Rl/Rn) versus tn—tl plot. The affinity constant of the GST-GAK/cyclin G interac-
tion was calculated from K¿ = k¿i¡,Jkass. 
G antibody, or to weak association of cyclin G with CDK5 in 
vivo. A Western blot analysis also detected association of 
GAK with CDK5 in vivo, but here again this interaction 
appeared weak (lane 6). Association of cyclin D and cyclin 
E with CDK5 was also detected (lanes 2 and 4) as reported 
previously in human fibroblast cells (WI38) [25] and mouse 
neural cell extracts [26]. 
To investigate whether GAK associates with other compo-
nents of the cyclin-CDK complex, the immunoprecipitates 
obtained with relevant antibodies were analyzed by Western 
blotting using an anti-GAK monoclonal antibody (1C2) (Fig. 
3C). Among the antibodies tested, GAK seems to associate 
only with CDK5 (lane 6) and cyclin G (lane 12). The band for 
CDK5 (lane 6) is very strong, probably as a result of the high 
quality of the anti-CDK5 monoclonal antibody. Association 
of GAK with cyclin G was also confirmed by the detection of 
the GAK band in an immunoprecipitate obtained with the 
anti-cyclin G polyclonal antibody, pGpep (lane 12). The asso-
ciation of GAK with other components of cyclin/CDK com-
plexes, such as cyclin A, cyclin C, cyclin D2, cyclin D3, cyclin 
F, cyclin H or cyclin I, whose antibodies were not available 
for us, remains to be tested. 
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3.4. Analysis of the cyclin G-GAK interaction using the 
BIA-core system 
To analyze the kinetics of the cyclin G-GAK interaction in 
vitro, the GST fusion proteins of cyclin G and GAK were 
purified to homogeneity. GAK and cyclin G proteins without 
the GST portion were also prepared by digestion of GST-
GAK or GST-cyclin G with thrombin. GST-GAK is suscep-
tible to protease attack in E. coli cells as shown in Fig. 2B. 
For this reason, we primarily obtained a truncated form of 
~ 6 0 kDa (full size GST-GAK is ~ 190 kDa) that retained, 
nonetheless, histone HI kinase activity as will be described 
later. Therefore, the kinase domain seems to be conserved. 
On the other hand, the affinity-purified cyclin G, after remov-
al of the GST portion by treatment with thrombin, displayed 
a single band at the expected size on SDS-PAGE (data not 
shown). Analysis by surface plasmon resonance biosensor 
technology [11,27-29] suggested that GAK directly associates 
with GST-cyclin G, probably via the kinase domain at the N-
terminus of the molecule. In this experiment, anti-GST anti-
body was covalently attached to the dextran matrix of a BIA-
core sensor chip to assess the association at a neutral pH 
value. The binding of the GST-GAK fusion protein to the 
antibody and the association of subsequently applied cyclin 
G with GST-GAK were monitored as a change in refractive 
index. The resonance signal during the injection of cyclin G 
and the displacement of the baseline during the subsequent 
rinsing process indicate a stable association between GAK 
and cyclin G. In the negative control experiment, in which a 
yeast DNA binding protein, Hacl [30], was used, no binding 
of Hacl to GAK was observed, as shown by an overlay pres-
entation of the resonance signal (Fig. 4A). Analysis of the 
association and dissociation phases of the interaction revealed 
an association rate of 6483 M _ 1 s_ 1 and a dissociation rate of 
2.57 Xl0~3 s"1 (Fig. 4B,C). The Kd value calculated from 
these rate constants was 397 nM (Fig. 4C), suggesting that 
GAK and cyclin G form a stable complex in vivo. 
Direct association of immobilized GST-CDK5 with GST-
free cyclin G was also examined by BIAcore system, but we 
could not detect any stable association between these two 
molecules (data not shown). It remains to be established 
whether the association between the affinity-purified cyclin 
G and CDK5 proteins that were prepared by expression in 
E. coli cells requires some modifications such as phosphoryl-
ation, or their association is merely indirect. 
4. Discussion 
Here we report the existence of a novel association partner 
of the cyclin-CDK complex that we refer to as GAK. We have 
demonstrated and confirmed the association of cyclin G with 
GAK in vivo by reciprocal immunoprecipitation and Western 
blot analysis in four different experiments as shown in Fig. 
3A-i (lane 3), Fig. 3A-ii (lane 1), Fig. 3A-iii (lane 3) and Fig. 
3C (lane 12). We also demonstrated in vitro, using the BIA-
core system, that the interaction was direct (Fig. 4). Further-
more, we found that GAK also associates with the CDK5 
complex (Fig. 3B,C, lanes 6) by reciprocal immunoprecipita-
tion and Western blot analysis. GAK migrated to a position 
corresponding to a molecular mass of 160 kDa in SDS-
PAGE, a size that coincided with one of the unidentified 
association partners of CDK5 reported previously [31]. It is 
feasible that GAK corresponds to their 180 kDa protein. In 
fact, we were able to detect a single band of 160 kDa in silver-
stained SDS-PAGE gels in immunoprecipitates of NRK cell 
extracts obtained with either anti-CDK5 or anti-GAK anti-
bodies (data not shown). 
It has been reported previously that p35, a cyclin-like pro-
tein, is the primary association partner of CDK5 in neural 
tissues [31,32]. As CDK5 is ubiquitous, one would expect 
that cyclins other than p35 function in non-neural tissues 
such as NRK cells as the regulatory subunit of CDK5. We 
demonstrated here by immunoprecipitation and Western blot 
analysis that cyclin G associates with the CDK5 complex in 
NRK cells. However, the BIAcore analysis suggested that 
their association is not stable at least under the conditions 
we used here. Therefore, cyclin G may not be the authentic 
CDK5 regulatory subunit of CDK5 in NRK cells. In fact, our 
preliminary kinase assays using histone HI as a substrate 
demonstrated that cyclin G constitutes only a part of the 
kinase activity of CDK5 (data not shown). This property of 
cyclin G is similar to that of cyclin D and cyclin E, with which 
CDK5 associates [25,26], but no regulatory action on the 
kinase activity was reported so far. 
GAK harbors several noticeable amino acid sequences of 
potential interest. Firstly, it possesses a protein kinase domain 
which resembles that of Nekl, CDK2, Plk and Tsk-1. Con-
sidering the absence of the PSTAIR motif in GAK, it is evi-
dent that GAK does not belong to the CDK family. Secondly, 
it harbors two putative dinucleotide-binding motifs in the kin-
ase domain suggesting that GAK activity is somehow modu-
lated by dinucleotides such as ADP or GDP. Thirdly, a phos-
phorylation recognition site for a tyrosine kinase is located at 
position 403^110 (KGDLDISY) [20-22] at the left end of the 
TAG domain. Fourthly, it contains a leucine zipper motif in 
the middle of the molecule whose physiological meaning is 
unknown at this stage. Fifthly, the amino acid sequence in 
the middle part of GAK resembles tensin and auxilin. 
Tensin is an actin-binding component of the focal adhesion 
plaque, which is an anchorage point of the plasma membrane 
to the substratum. The focal adhesion plaque is usually asso-
ciated with cytoplasmic microfilament bundles, and stress fi-
bers, composed of bundles of actin filaments, are often an-
chored to these regions via an association with tensin [33]. 
Tensin includes both phosphorylated tyrosine residues and a 
Src homology 2 (SH2) domain, which is shared by a number 
of signal transduction proteins [34]. It is suggested that tensin 
may link signal transduction pathways with the cytoskeleton 
by possessing both actin-binding and phosphotyrosine-bind-
ing properties and being itself a target for tyrosine kinases 
[35]. Since GAK also has tensin-like properties such as an 
actin-binding domain and a target site for tyrosine kinases, 
it is conceivable that GAK plays a similar role in the cyto-
skeletal signal transduction pathway. Absence of the SH2 do-
main in GAK and differences in the recognized amino acid 
sequences around the target tyrosine residue indicate that the 
physiological roles of tensin and GAK as signal transducers 
may be somewhat distinct. The presence of a Ser/Thr kinase 
domain at the N-terminal portion of the molecule suggests 
that GAK plays a more positive role as a modulator of signal 
transduction, by relaying the phosphorylation signal from an 
unidentified tyrosine kinase to unidentified GAK phosphoryl-
ation targets. The examination of these possibilities will be the 
subject of our future experiments. 
Auxilin is a coat protein of brain clathrin-coated vesicles, 
Y. Kanaoka et al.lFEBS Letters 402 (1997) 73-80 
which directly interacts with the heavy chain of clathrin, sup-
porting its assembly into regular cages, and is involved in the 
regulation of nerve-cell-specific functions [17]. The putative 
consensus sequence for the SH3 domain (PXXXPPXXP) 
[36] found in auxilin was not detected either in G A K or in 
tensin. The C-terminal portion of G A K (132 residues) closely 
resembles auxilin and the secondary structure of this region is 
shown to be predominantly a-helical [17]. Inasmuch as the 
main body of G A K is similar to auxilin, it is feasible that 
G A K actually binds to cytoskeletal membranous structures. 
It is hoped that our future investigations will reveal the phys-
iological significance of these structural resemblances in rela-
tion to the role of cyclin G. 
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